Victorian Clinical Genetics Services (VCGS)
Leonhard Gruenschloss is an experienced AI and Machine Learning Software Engineer currently working at Victorian Clinical Genetics Services (VCGS) since April 2025, focusing on accelerating rare disease diagnosis through AI applications in genomics. Previous roles include Staff Software Engineer at Neara, where leadership of the network model stream involved modeling electric utility grids, and Software Lead at the Garvan Institute of Medical Research, overseeing cloud-based genomic analysis software. Leonhard's extensive background at Google includes managing teams on significant projects like Census and Cloud Spanner, as well as experience as a researcher at Weta Digital and a Graphics Software Engineer at mental images/NVIDIA. Leonhard began a career with a Student Trainee position at Daimler and holds a Master's degree in Computer Science from Ulm University.
This person is not in any teams
This person is not in any offices
Victorian Clinical Genetics Services (VCGS)
Victorian Clinical Genetics Services (VCGS) is a specialist prenatal, childhood and adult genetics service. We are an Australian not-for-profit subsidiary of Murdoch Children’s Research Institute (MCRI) and one of the largest contributors driving genetic healthcare, research and policy in the country. We marked our 34th anniversary in July 2022 and acknowledge our fantastic donors, funders, supporters and collaborators over this time, including the global genetics community, and the Australian Federal and Victorian State governments. Located on site at The Royal Children’s Hospital (RCH) Melbourne, we provide an integrated genetic consultation, counselling, testing and diagnostic service for children, adults, families, and prospective parents. Our unique service includes the ability to draw on specific expert knowledge from Melbourne Children’s campus partners RCH and The University of Melbourne, providing individuals and families with accessible and high quality healthcare. As a pioneering not-for-profit organisation, all our proceeds go back into translational medical research so that we can continue to develop innovative solutions to complex genetic health challenges.